Nerve conduction studies in patients treated with cis-diamminedichloroplatinum(II): a preliminary report.
We performed serial histories, physical examinations, and nerve conduction studies on seven cancer patients who were treated with cis-diamminedichloroplatinum(II). Total cumulative doses ranged from 200 to 350 mg/m2. In nerve conduction studies, three of seven patients showed subclinical, predominantly sensory, changes compatible with a peripheral neuropathy.